Navigation Links
Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Date:8/31/2009

BASKING RIDGE, N.J., Aug. 31 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the results of a Phase 2a clinical trial of their lead product, the anticoagulant system REG1, were released at the European Society of Cardiology Congress in Barcelona, Spain. The results, detailed in a poster entitled, "First Clinical Application of an Actively Reversible Direct Acting Factor IXa inhibitor in Elective Percutaneous Intervention", were presented by Dr. Mauricio Cohen, lead investigator of the study from the University of Miami-Miller School of Medicine. The poster was presented on Sunday, August 30, 2009.

This was the first study to evaluate REG1 in a clinical setting involving percutaneous coronary intervention (PCI). REG1 is a two component system consisting of RB006, a direct FIXa inhibitor and RB007, the active, specific control agent for RB006. This phase 2a study (REVERSAL-PCI) was an open-label, randomized, multicenter study that evaluated feasibility and safety during elective PCI comparing the REG1 anticoagulant system with unfractionated heparin in patients with coronary artery disease. All 26 patients in the study received aspirin and clopidogrel as background therapy. The primary endpoint of the study was major bleeding within 48 hours. Important secondary endpoints were a composite of death, myocardial infarction or urgent target vessel revascularization within 14 days and pharmacodynamic measures. The three arms of the study were designed to measure both total and partial anticoagulant reversal, with all REG1 subjects undergoing planned early arterial catheter sheath removal.

The study demonstrated that the REG1 System enabled safe and effective PCI. All procedures were successfully completed in the REG1 cohorts with no signs of catheter or guidewire thrombosis. Coagula
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
2. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
3. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
4. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
6. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
7. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
8. Neurocrine Biosciences Presents Elagolix Data
9. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... --  Heska Corporation (NASDAQ: HSKA ) - ... advanced veterinary diagnostic and other specialty veterinary products , ... attend The Benchmark Company, LLC,s Micro Cap Discovery Conference on ... at The Palmer House Hilton, 17 E. Monroe Street, ... p.m. Please email hska@haydenir.com or contact your Benchmark ...
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... announces that a new market research report is ... Drug Discovery in Emerging Markets ... markets have represented important growth opportunities for the ... the extent to which this has been accompanied ...
... Calif., Jan. 11, 2011 STAAR Surgical Company (Nasdaq: ... marketer of minimally invasive ophthalmic products, today announced that ... 31, 2010 to exceed $14.2 million. Revenues for the ... over 2009 revenues, driven by an increase of approximately ...
Cached Medicine Technology:Reportlinker Adds Innovative Drug Discovery in Emerging Markets 2Reportlinker Adds Innovative Drug Discovery in Emerging Markets 3STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million 2STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million 3STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million 4
(Date:11/27/2014)... 2014 (HealthDay News) -- Thanksgiving meals can pose a ... diet, an expert says. Many traditional Thanksgiving dishes ... sauce -- are gluten-free, but "when it comes to ... be considered," Dr. Anca Safta, director of the Gluten ... Medical Center in North Carolina, said in a center ...
(Date:11/27/2014)... New York, NY (PRWEB) November 27, 2014 ... devoted to offering stylish, comfortable and high functioning compression socks, ... line. The newly-released socks use an innovative Gradient Pressure (TM) ... freshly oxygenated blood. , VIM & VIGR’s commitment to adding ... thought of as just functional recently caught the eye of ...
(Date:11/27/2014)... NV (PRWEB) November 27, 2014 Now ... shopping season has officially launched, Emassagechair.com has ... Cyber Monday Discount Event. , Negotiating on behalf ... with top massage chair brands, Emassagechair.com has generated significant ... best deals and biggest discounts yet. , Shoppers are ...
(Date:11/27/2014)... 2014 Two international trainers and lecturers ... will help one person with significant needs but limited ... and Dr. Mamaly Reshad of the Anacapa Dental Art ... a website devoted to helping dentist learn about using ... would be devoted to helping a patient who has ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “Wekho” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review ... locations instead of people. , An interesting new way to ... iOS and Android devices. It’s called Wekho and it’s ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2
... ... , ... 2010 -- From self-published author Felicia J. Henderson comes a personal tale of despair, survival, ... book that will reach out to those who have experienced life’s trials and never lost ...
... ... volcano Eyjafjallajökull has not only interfered in the air traffic around the globe. ... the important booking season for tourism to Iceland, it has affected the bookings ... only seen few requests on holiday offers since the eruption had started and ...
... Calif.) Extremely obese children have a 40 percent ... who are moderately obese have a 30 percent higher ... to a Kaiser Permanente study published online in the ... large population-based study establishes an association between obesity and ...
... ... three dental programs in the nation to receive the “Best Practice” award from Safety Net ... have translated into positive improvements for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s ...
... ... Patient Care , ... NY (Vocus) July 8, 2010 -- As nursing assumes an increasingly prominent role in the ... announced today it will soon require newly hired nurses to have a Bachelor of Nursing ...
... USA (July 8, 2010) To provide authors additional ... abstracts is now extended until July 31 for the ... held December 2-4 at the Washington Marriott Hotel in ... symposium on the following five topics: "Virus biology," "Pandemics, ...
Cached Medicine News:Health News:Self-Published Author Shares Her Personal Story of Hope Amidst Despair 2Health News:Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland" 2Health News:Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland" 3Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 2Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 3Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree 2Health News:North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree 3Health News:Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: